Alumis

ALMSPhase 3

Alumis is advancing a late-stage portfolio of targeted therapies designed to transform treatment for immune-mediated diseases. The company leverages a proprietary data analytics platform integrating genetic, genomic, proteomic, and clinical insights to drive smarter therapeutic development. With a seasoned leadership team and a lead asset in Phase 3 for psoriasis, Alumis aims to deliver optimized therapies that help millions worldwide live healthier, fuller lives.

Market Cap

$2.9B

Focus

Small Molecules

ALMS · Stock Price

USD 25.06+11.76 (+88.42%)

Historical price data

AI Company Overview

Technology Platform

A proprietary data analytics platform that integrates genetic, genomic, proteomic, biological, and clinical insights to identify optimal targets, patient populations, and endpoints for developing targeted therapies in immune-mediated diseases.

Pipeline Snapshot

13 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
ESK-001 + Apremilast + Placebo	Plaque Psoriasis	Phase 3
Open-Label ESK-001 + Blinded ESK-001 + Placebo	Plaque Psoriasis	Phase 3
ESK-001 + Placebo + Apremilast	Plaque Psoriasis	Phase 3
ESK-001	Uveitis Posterior Non-Infectious	Phase 2
ESK-001	Plaque Psoriasis	Phase 2

Funding History

Total raised: $707M

IPO$248MUndisclosedJun 28, 2024

Series B$259MForesite CapitalDec 15, 2023

Series A$200MForesite CapitalJan 15, 2022

Opportunities

The primary near-term opportunity is the successful development and commercialization of envudeucitinib in the large psoriasis market.

Longer-term, the proprietary precision platform offers the opportunity to expand the pipeline into other immune-mediated diseases with high unmet need, potentially through new indications for existing assets or the discovery of novel therapies.

Risk Factors

Key risks include clinical trial failure or safety issues with the lead candidate, regulatory hurdles, intense competition in the immunology space, and the financial risks associated with funding late-stage development as a pre-revenue company.

Competitive Landscape

Alumis faces competition from large pharma and biotech companies with approved and pipeline therapies for immune-mediated diseases. In psoriasis, direct competitors include Bristol Myers Squibb (Sotyktu) and AbbVie (Rinvoq). The company aims to differentiate through the precision of its therapies enabled by its integrated data analytics platform.

Publications

Patents

Pipeline